We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Device Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
» Boehringer Sues Amneal to Block Generic Aggrenox
Boehringer Sues Amneal to Block Generic Aggrenox
August 13, 2014
Pharmaceuticals
Commercial Operations
Boehringer Ingelheim is suing Amneal Pharmaceuticals over its bid to make a generic version of the brand manufacturer’s anti-stroke drug Aggrenox.
To View This Article:
Login
Email
Password
Register
Remember Me
Forgot your password?
Subscribe To Generic Line
Buy This Article Now
Add this article to your cart for $40.00
Upcoming Events
27
Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27
Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09
Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10
Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11
Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
17
Feb
Effective Auditing for Manufacturing Quality
Featured Products
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
Featured Stories
Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly
Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19
Regeneron’s Antibody Cocktail Shows Efficacy as COVID-19 Treatment
FDA to Review Berkshire’s 510(k) Submission for Remote Drug-Delivery System
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
